Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours
复制标题
DOI：
10.1016/s0959-8049(01)00073-9
复制
发表时间：
2001-05-01
影响因子：
8.4
通讯作者：
Rougier, P
中科院分区：
文献类型：
--
作者：
Aparicio, T;Ducreux, M;Rougier, P
一些研究表明生长抑素类似物在神经内分泌肿瘤（NET）中具有抗肿瘤活性。本研究的目的是评估生长抑素类似物的抗肿瘤疗效的患者记录进行性肿瘤。连续35例记录肿瘤进展的患者接受生长抑素类似物治疗。患者分为两组。在第1组中，肿瘤进展迅速（3个月内病变表面积增加50%或更多），而在第2组中，肿瘤进展较慢（3个月内病变表面积增加小于50%，但6个月内大于25%）。治疗由皮下（s.c.）奥曲肽，17名患者100 μ g，每日三次，11名患者肌肉注射兰瑞肽，30 mg/每14天，7名患者在随访期间连续使用两种生长抑素类似物。原发肿瘤部位为小肠（n = 12）、胰腺（n = 13）。肺（n = 5）。其他部位（n = 5）。18例患者有类癌综合征，伴有潮红和/或腹泻。中位治疗持续时间为7个月。3例患者因副作用而停止治疗。1例患者（3%）获得部分缓解，20例患者（57%）的疾病稳定，中位持续时间为11个月（6-48个月）。第1组患者在6个月时稳定的频率明显低于第2组患者（分别为4/12和13/17，P
A few studies have suggested an antitumour activity of somatostatin analogues in neuroendocrine tumours (NET). The aim of this study was to evaluate the antitumour efficacy of somatostatin analogues in patients with documented progressive tumours. 35 consecutive patients with documented tumour progression were treated with somatostatin analogues. Patients were classified into two groups. In Group 1, tumours were progressing rapidly (an increase of 50% or more in the lesion surface area in 3 months) and in Group 2, tumours were progressing more slowly (an increase of less than 50% in the lesion surface area in 3 months but greater than 25% in 6 months). Treatment consisted of subcutaneous (s.c.) octreotide, 100 mug thrice daily for 17 patients, intramuscular lanreotide, 30 mg/every 14 days for 11 patients and for 7 patients both somatostatin analogues were used successively during the follow-up. Primary tumour sites were the small intestine (n = 12), pancreas (n = 13). lungs (n = 5). and other sites (n = 5). 18 patients had the carcinoid syndrome with flushing and/or diarrhoea. The median duration of treatment was 7 months. Treatment was discontinued in 3 patients due to side-effects. One patient (3%) achieved a partial response and the disease was stabilised in 20 patients (57%) for a median duration of 11 months (6-48 months). Stabilisation of patients in Group 1 was significantly less frequent at 6 months than that of patients in Group 2 (4/12 and 13/17 respectively, P